Xeris Biopharma (NASDAQ:XERS) Director John Johnson Sells 135,400 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director John Johnson sold 135,400 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.22, for a total transaction of $977,588.00. Following the completion of the transaction, the director directly owned 698,083 shares in the company, valued at $5,040,159.26. This trade represents a 16.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Xeris Biopharma Trading Up 4.7%

XERS traded up $0.33 during trading on Friday, hitting $7.34. 3,967,816 shares of the company traded hands, compared to its average volume of 2,483,810. The company has a market cap of $1.22 billion, a PE ratio of -73.39 and a beta of 0.57. The stock’s 50-day simple moving average is $7.89 and its two-hundred day simple moving average is $6.85. Xeris Biopharma Holdings, Inc. has a 1 year low of $3.14 and a 1 year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.01 by ($0.01). The business had revenue of $74.38 million for the quarter, compared to analyst estimates of $74.19 million. Equities analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Institutional Trading of Xeris Biopharma

A number of institutional investors have recently bought and sold shares of XERS. AlphaQuest LLC purchased a new position in Xeris Biopharma during the third quarter worth $35,000. FORA Capital LLC bought a new stake in shares of Xeris Biopharma in the 1st quarter worth about $60,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares during the period. State of Alaska Department of Revenue bought a new position in Xeris Biopharma during the 3rd quarter valued at about $68,000. Finally, Tower Research Capital LLC TRC grew its holdings in Xeris Biopharma by 913.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock valued at $81,000 after purchasing an additional 15,678 shares during the last quarter. 42.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on XERS. Barclays initiated coverage on Xeris Biopharma in a research note on Monday, December 8th. They issued an “overweight” rating and a $9.00 price objective on the stock. Piper Sandler raised their target price on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Oppenheimer reiterated an “outperform” rating and set a $18.00 price objective on shares of Xeris Biopharma in a research report on Friday, November 7th. Finally, Zacks Research cut shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 30th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.